TY - JOUR
T1 - Clinicopathological significance of S100A10 expression in lung adenocarcinomas
AU - Katono, Ken
AU - Sato, Yuichi
AU - Jiang, Shi Xu
AU - Kobayashi, Makoto
AU - Saito, Keita
AU - Nagashio, Ryo
AU - Ryuge, Shinichiro
AU - Satoh, Yukitoshi
AU - Saegusa, Makoto
AU - Masuda, Noriyuki
PY - 2016
Y1 - 2016
N2 - Background: S100A10, of the S100 protein family, is reported to be involved in cancer cell invasion and metastasis. The aims of the present study were to immunohistochemically examine S100A10 expression in surgically resected lung adenocarcinomas, and evaluate any relationships with clinicopathological parameters and prognosis of patients. Materials and Methods: S100A10 expression was immunohistochemically studied in 202 consecutive resected lung adenocarcinomas, and its associations with clinicopathological parameters were evaluated. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate the effect of S100A10 expression on survival. Results: S100A10 expression was detected in 65 of the 202 (32.2%) lung adenocarcinomas, being significantly correlated with poorer differentiation (P =0.015), a higher pathological TNM stage (stages II and III) (P=0.004), more frequent and severe intratumoral vascular invasion (P=0.001), and a poorer prognosis (P=0.030). However, S100A10 expression was not an independent predictor of survival after controlling for clinicopathological factors. Conclusions: The present study reveals that S100A10 is expressed in a subset of lung adenocarcinomas, and this is related to some clinicopathological parameters, although further studies are required to confirm the correlation between S100A10 expression and prognosis of lung adenocarcinoma patients.
AB - Background: S100A10, of the S100 protein family, is reported to be involved in cancer cell invasion and metastasis. The aims of the present study were to immunohistochemically examine S100A10 expression in surgically resected lung adenocarcinomas, and evaluate any relationships with clinicopathological parameters and prognosis of patients. Materials and Methods: S100A10 expression was immunohistochemically studied in 202 consecutive resected lung adenocarcinomas, and its associations with clinicopathological parameters were evaluated. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate the effect of S100A10 expression on survival. Results: S100A10 expression was detected in 65 of the 202 (32.2%) lung adenocarcinomas, being significantly correlated with poorer differentiation (P =0.015), a higher pathological TNM stage (stages II and III) (P=0.004), more frequent and severe intratumoral vascular invasion (P=0.001), and a poorer prognosis (P=0.030). However, S100A10 expression was not an independent predictor of survival after controlling for clinicopathological factors. Conclusions: The present study reveals that S100A10 is expressed in a subset of lung adenocarcinomas, and this is related to some clinicopathological parameters, although further studies are required to confirm the correlation between S100A10 expression and prognosis of lung adenocarcinoma patients.
KW - Lung adenocarcinoma
KW - Plasminogen receptor
KW - Prognosis
KW - S100A10
UR - http://www.scopus.com/inward/record.url?scp=84957964993&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84957964993&partnerID=8YFLogxK
U2 - 10.7314/APJCP.2016.17.1.289
DO - 10.7314/APJCP.2016.17.1.289
M3 - Article
C2 - 26838226
AN - SCOPUS:84957964993
SN - 1513-7368
VL - 17
SP - 289
EP - 294
JO - Asian Pacific Journal of Cancer Prevention
JF - Asian Pacific Journal of Cancer Prevention
IS - 1
ER -